INTERVENTIONAL ONCOLOGY SOLUTIONS MARKET ANALYSIS

Regional Analysis

Interventional Oncology Solutions Market Regional Analysis:-

North America is expected to hold dominant position in the global interventional oncology solutions market over the forecast period. This is owing to increasing mergers & acquisition and research collaboration between manufacturers and universities in the region to develop novel products. For instance, in 2015, Boston Scientific enhanced its interventional oncology portfolio by acquiring spherical embolic technologies, Embozene and Oncozene microspheres, which were developed by Celo Nova Biosciences. These spheres are designed to prevent flow of blood to the targeted tissue and also reduce growth of tumors. Moreover, in 2016, Philips collaborated with Yale School of Medicine to bring new innovations in the field of interventional oncology. Liver cancer is one of their main focus areas, as TACE (Trans arterial Chemoembolization), an alternative and minimally invasive technique to treat liver cancer patients, it has shown better results than chemotherapy. TACE is a minimally invasive procedure which is performed in interventional radiology to restrict a tumors blood supply. Small embolic particles which are coated with chemotherapeutic drugs are injected through a catheter into the arteries which supply blood to the tumor. Chemotherapeutic drugs block the supply of blood and induce cytotoxicity i.e. attacking the tumor in several ways. TACE involves administration of embolic beads and chemotherapy agents to gradually block arteries feeding the tumor, which further causes death of the tumor.

Europe interventional oncology solutions market is expected to exhibit high growth over the forecast period, owing to high cancer prevalence in the region. According to a study conducted by World Health Organization (WHO) in 2016, Europe has over 753,600 people diagnosed with cancer. Furthermore, key players in the region are focusing on launching new products, which is another factor supporting growth of the market. For instance, in 2017, Elekta, a Sweden-based company, launched Elekta Unity MR-linac, which relies on a Philips 1.5 Tesla MRI Machine. During therapy sessions, the machine produces diagnostic level image quality. This device provides more precise treatment, which includes targeting of higher doses on sensitive areas containing multiple organs and also observation of radiation affecting tumor. One of the most important application of this device is the functional MRI, which helps doctor to observe how the treatment is working on the tumor and it also helps to evaluate the rate of blood flow through the tumor, which indicates if the tissue is alive or is showing some change due to the therapy.